Abstract:Cullin-RING E3 ligases (CRLs) are the major components of ubiquitin-proteasome system, responsible for ubiquitylation and subsequent degradation of thousands of cellular proteins. CRLs play vital roles in the regulation of multiple cellular processes, including cell cycle, cell apoptosis, DNA replication, signalling transduction among the others, and are frequently dysregulated in many human cancers. The discovery of specific neddylation inhibitors, represented by MLN4924, has validated CRLs as promising targets for anti-cancer therapies with a growing market. Recent studies have focused on the discovery of the CRLs inhibitors by a variety of approaches, including high through-put screen, virtual screen or structure-based drug design. The field is, however, still facing the major challenging, since CRLs are a large multi-unit protein family without typical active pockets to facilitate the drug design, and enzymatic activity is mainly dependent on undruggable protein-protein interactions and dynamic conformation changes. Up to now, most reported CRLs inhibitors are aiming at targeting the F-box family proteins (e.g., SKP2, β-TrCP and FBXW7), the substrate recognition subunit of SCF E3 ligases. Other studies reported few small molecule inhibitors targeting the UBE2M-DCN1 interaction, which specifically inhibits CRL3/CRL1 by blocking the cullin neddylation. On the other hand, several CRL activators have been reported, such as plant auxin and immunomodulatory imide drugs, thalidomide. Finally, proteolysis-targeting chimeras (PROTACs) has emerged as a new technology in the field of drug discovery, specifically targeting the undruggable protein-protein interaction. The technique connects the small molecule that selectively binds to a target protein to a CRL E3 via a chemical linker to trigger the degradation of target protein. The PROTAC has become a hotspot in the field of E3-ligase-based anti-cancer drug discovery.

Discovery of Nedd4 auto-ubiquitination inhibitors

Discovery of small molecule inhibitors of neddylation catalyzing enzymes for anticancer therapy

Design, synthesis, and biological evaluation of Nedd4 E3 ubiquitin ligase small molecule inhibitors

Phage display to identify Nedd8-mimicking peptides as inhibitors of the Nedd8 transfer cascade.

Profiling the Cross Reactivity of Ubiquitin with the Nedd8 Activating Enzyme by Phage Display.

Comparative analysis of the catalytic regulation of NEDD4-1 and WWP2 ubiquitin ligases

Discovery of a small molecule inhibitor of cullin neddylation that triggers ER stress to induce autophagy

Targeting DCN1-UBC12 Protein-Protein Interaction for Regulation of Neddylation Pathway

Progress in the researches for antitumor NEDD8 activating enzyme inhibitors

Anticancer Drug Discovery by Targeting Cullin Neddylation

Allosteric auto-inhibition and activation of Nedd 4 family E 3 ligase Itch

Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold.

System-Wide Modulation of HECT E3 Ligases with Selective Ubiquitin Variant Probes.

Targeting Neddylation Pathways to Inactivate Cullin-RING Ligases for Anticancer Therapy

The many substrates and functions of NEDD4-1

Protein neddylation and its role in health and diseases

Effective Virtual Screening Strategy Toward Covalent Ligands: Identification of Novel NEDD8-Activating Enzyme Inhibitors

A lysine-to-arginine mutation on NEDD8 markedly reduces the activity of cullin RING E3 ligase through the impairment of neddylation cascades.

Review of NEDDylation inhibition activity detection methods

Protein Neddylation and Its Alterations in Human Cancers for Targeted Therapy.

Targeting Cullin-RING E3 ligases for anti-cancer therapy:efforts on drug discovery